5-year-plan to bring HIV vaccine to market
Proponents of the strategy said it was urgent, because two ongoing clinical trials for a potential HIV vaccine are looking promising.“Once we have a vaccine, we can’t waste time,” said Bekker.
We have to deal with regulatory bodies, governments and health systems.
“We have to deal with regulatory bodies, governments and health systems.
Much of that work can be done up front.”The Global HIV Vaccine Enterprise, a US-based body which oversees the strategy, has received funding from the US National Institutes of Health and the Bill and Melinda Gates Foundation.
Much of that work can be done up front.” Linda-Gail BekkerRelated topics HIV/AIDSHealthMedicineR&DA comprehensive worldwide strategy to accelerate the process of creating a vaccine against HIV was launched in Spain this month.The Global HIV Vaccine Enterprise Strategic Plan will run from 2018 to 2023, and aims to speed up vaccine rollout by making it easier to do R&D and complete the legal requirements of marketisation.